SynthesisFrontiers in immunology2026
Association between OLD and IBD: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to systematically evaluate the bidirectional association between obstructive lung diseases (OLD) [including chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis] and inflammatory bowel disease (IBD) [including Crohn's disease (CD) and ulcerative colitis (UC)]. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a systematic search of the PubMed, Embase, and Cochrane Library databases to identify relevant observational studies published up to 30 June 2025. The included studies were cohort studies, case-control studies, and cross-sectional studies that reported relative risk (RR), hazard ratio (HR), or odds ratio (OR) with 95% confidence intervals (CIs). Study quality was assessed using the Newcastle-Ottawa Scale (NOS), and data were analyzed using random effects or fixed effects models. HRs, RRs, and ORs were analyzed separately according to the direction of association and the disease subtype. Results: A total of 30 observational studies were included. In the estimate-stratified analyses, IBD was associated with an increased risk of subsequent COPD, while COPD was generally associated with increased risks of subsequent CD and UC, although the COPD-to-CD and COPD-to-UC analyses showed substantial heterogeneity. For bronchiectasis, available evidence suggested a positive association with IBD; however, the pooled estimate for IBD and subsequent bronchiectasis was imprecise and should be interpreted with caution. For asthma, the association was more consistent: IBD was associated with an increased risk of subsequent asthma in both HR- and OR-based analyses, and asthma was also associated with subsequent IBD in the HR-based analysis. The bidirectional association was generally stronger and more consistent for CD than for UC. Conclusion: This systematic review and meta-analysis supports positive associations between OLD and IBD, particularly for COPD with the IBD subtypes and for asthma with IBD, especially CD. These associations should be interpreted according to the OLD subtype and the age context. Clinicians should be attentive to respiratory comorbidities in patients with IBD, and appropriate respiratory symptom assessment or screening may help early identification and management. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251169706.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.